top of page

Investment Opportunity in Game-Changing AI Technology for Non-Invasive Multi-Cancer Early Detection

Listing Code:

XYLAB1E

State:

Not Disclosed

Category:

Medical Labs

Asking Price:

-

Revenue:

-

XYLAB1E
Company Overview

PRIME exits and American Healthcare Capital are thrilled to serve as the representative for a cutting-edge, highly specialized medical lab that has an unmatched, pioneering technique using AI technology for detecting cancer early on, long before any signs or symptoms materialize. The Company is poised to transform the fight against cancer, with the potential to save countless lives. Leveraging their proprietary AI platform, the Company has attained unrivaled precision (up to 99%) in cancer prevention, screening, and diagnosis utilizing non-invasive blood and urine testing, unlike current invasive procedures such as biopsy.


The Problem

Even though cancer treatments have significantly progressed, cancer remains the second leading cause of mortality worldwide, resulting in approximately 10 million deaths in 2020 (which amounts to about 19.5 deaths per minute). In order to save millions of lives from cancer, early detection is essential to improving the effectiveness of treatments, reducing the mortality rate, and decreasing invasive surgical procedures. The lack of reliable early cancer detection tests has been a major obstacle in the fight against this disease. The immense loss of life from cancer and the suffering it inflicts upon families is tragic enough, but the impact of cancer extends even further. Over the next 30 years, cancer is projected to cost the world $25 trillion. In the U.S. alone, cancer deaths translate to roughly $100 billion in lost earnings annually. Moreover, the total cost of cancer care in the U.S. was about $174 billion in 2020 ($1 trillion when including indirect costs). So, while progress has been made, cancer continues to take an enormous physical, emotional, and financial toll.


The Solution

Over the past 7 years, the Company has dedicated itself to refining its proprietary, AI-powered (Machine Learning) Multiple Biomarkers Disease Activity Algorithms (MBDAA). They pursued this with three main objectives in mind:

– To diagnose cancer with near 100% accuracy (as measured by sensitivity and specificity), enabling detection even before symptoms appear.

– To allow a single test to perform multiple screenings (concurrently detecting over 50 different cancers).

– To use non-invasive methods (no endoscopy, biopsy or surgery – just blood, urine, questionnaires and body measurement data).

– To make diagnosis affordable and quick (results in 48 hours), improving access and commercial viability.


The Opportunity and the Market Size

There is a massive market opportunity for early cancer detection and diagnosis in developed countries and for all types of cancers. According to Grandview Research, the global cancer diagnostic market is estimated at $107.4 B, while cancer early detection market is valued at USD at almost $1 Billion, and they are expected to expand at a compound annual growth rate (CAGR) of 6.6% and 15.80% respectively, from 2023 to 2030.

According to the Company, validated with other publicly published data, the potential market only in the U.S. is over $ 90 Billion/year, just considering the routine annual screening associated with Multi-Cancer Early Detection for Breast Cancer and Colorectal Cancer.


The Management Team

The company’s executive leaders are a group of highly capable people with impressive histories and expertise. The management team includes experienced business executives who previously held top-tier executive and senior leadership roles at large multinational corporations. It also consists of scientists, doctors, biochemists, software developers, artificial intelligence experts, and professionals with experience in clinical trials and regulatory matters.


The Funding

In addition to the initial investments by the founders, the Company has raised $14.3 million in both Seed and Series A funding with a post-valuation of $129 million.


The Ask

The Company’s founders and management team, who have played integral roles in the development, planning, testing, scientific researching, validating, and confirming the effectiveness of the company’s comprehensive solution, are inviting a strategic financial sponsor to collaborate on the launch of products in the U.S., Europe, and eventually worldwide. The founders are open to raising capital through equity and exploring various deal structures to achieve their objective.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.

YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:

XYLAB1E

Listing Title:

Investment Opportunity in Game-Changing AI Technology for Non-Invasive Multi-Cancer Early Detection

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi

President/Founder

American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

bottom of page